March 1, 2023
Ono Pharmaceutical said on February 28 that it has filed its PD-1 inhibitor Opdivo (nivolumab) for an additional indication of malignant mesothelioma (excluding malignant pleural mesothelioma). The submission is supported by the results of an investigator-initiated PII trial, dubbed VIOLA,...read more